No Result

View All Result

No products in the cart.

Home Tag hematologic cancer

Tag: hematologic cancer

The CLL14 trial: longer progression-free survival for CLL patients with coexisting conditions treated with venetoclax

Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)

byNeel Mistryand1 others

August 30, 2023

1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% ...

#VisualAbstract: Chemoradiotherapy with carboplatin is more effective than cetuximab in head and neck squamous cell carcinoma

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

byTeddy Guo

October 19, 2022

Click to read this study in the Journal of Clinical Oncology.

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

byKathleen Lau

November 12, 2021

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

byJessie Willisand1 others

September 8, 2021

1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% ...

Severe subtype of acute lymphoblastic leukemia susceptible to FDA-approved kinase inhibitors

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

byNeel Mistryand1 others

August 17, 2021

1. 71% patients achieved complete remission or complete remission with incomplete recovery following KTE-X19 infusion. 2. The majority of adverse ...

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

byKathleen Lau

January 22, 2021

#VisualAbstract Higher rate of hematologic second primary malignancies developed in multiple myeloma patients who received autologous hematopoietic stem cell transplants

byKathleen Lau

January 21, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result

Tag: hematologic cancer

Lisocabtagene maraleucel may induce remission in relapsed chronic lymphocytic leukemia (CLL)

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

#VisualAbstract Lenalidomide in combination with R-CHOP is effective in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

KTE-X19 may induce remission in patients with relapsed or refractory B-cell lymphoblastic leukemia

#VisualAbstract Oral poly(ADP-ribose) polymerase inhibitors were associated with an increased risk of myelodysplastic syndrome and acute myeloid leukaemia over placebo treatment in patients with cancer

#VisualAbstract Higher rate of hematologic second primary malignancies developed in multiple myeloma patients who received autologous hematopoietic stem cell transplants

2MM+ All Access

Recent Reports

The medical literature, distilled daily.

Membership benefits